The structural heart device market was valued at the US $ 5.537 billion in 2019 and is expected to grow at a CAGR of 8.94 % over the forecast period to reach a total market size of US $ 10.086 billion by 2026.
Structured heart disease, also called structural cardiac disease, is the accumulation of heart conditions, including congenital heart disease, heart failure, and coronary artery disease. The medical field has advanced to the point where minimally invasive procedures are replacing open-heart surgical procedures, such as transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR). This market is driven by the high prevalence of target illnesses. There are many different kinds of structural heart diseases (SHD), ranging from acquired heart disease to innate heart disease (CHD) that include useful and structural abnormalities of the heart valves, proximal amazing vessels, and the chambers of the cardiovascular system. Valvular heart disease affects 2.5 percent of the American population.
An increase in structural heart diseases; advancements in technology; development of innovative devices, including annuloplasty rings and occluders; and the demand for minimally invasive surgical procedures lead to an increase in structural heart devices. For example, OSCOR, Inc. and Micro Interventional Devices, Inc. entered into a strategic partnership in March 2019 focused on developing and commercializing novel therapeutic approaches to structural heart disease, specifically MID's MIATM, Minimally Invasive Annuloplasty technology.
Growth Factors:
In addition to improved treatment options and longer lifespans, structural heart devices with advanced tissue heart valves are becoming more commonly used to repair and replace structural hearts. The advent of tissue aortic valve replacements, which use tissue valves, further improved patient outcomes for those who suffer from aortic regurgitation. For example, in November 2019, LivaNova PLC, a market leader in medical technology and innovation, announced it is no longer engaged in the Caisson Transcatheter Mitral Valve Replacement (TMVR) program and is restructuring its heart valve business to improve profitability and ensure continuity. A healthcare and sustainability investment firm, Gyrus Capital (Gyrus), announced an agreement with LivaNova in December 2020 where entities funded and controlled by Gyrus will acquire the business of LivaNova heart valves. Thus, the Company will be able to tailor its focus within its two primary platforms, neuromodulation and cardiovascular, and to devote more resources to executing opportunities within its pipeline.
These minimally invasive devices and techniques are preferred over open-heart surgeries, for instance, due to their minimally invasive nature. Cardiologists commonly perform modern minimally invasive procedures to treat structural heart diseases that include mitral valve replacement, aortic valve replacement, and prosthetic heart valve replacement services. For instance, In September 2021, Abbott, and its PorticoTM with FlexNavTM transcatheter aortic valve replacement (TAVR) system have been approved by the FDA for the treatment of patients with symptomatic, severe aortic stenosis. Such developments are boosting the market growth.
Restrain
Market growth is constrained by the high costs of advanced structural heart devices and the risks associated with the procedures. Since these devices are more expensive than their traditional counterparts, technology-advanced structural heart devices are not adopted at a rapid rate, especially in emerging economies.
Covid-19 Insights:
In older patients and those with comorbid conditions with structural heart disease, the Coronavirus Disease-2019 (COVID-19) poses an increased risk of adverse outcomes. While the COVID-19 pandemic plus the demand-supply crisis during the pandemic canceled or delayed many transcatheter interventions for structural heart disease. This has negatively impacted the market for structural heart device market.
| Report Metric | Details |
| Market size value in 2019 | US$5.537 billion |
| Market size value in 2026 | US$10.086 billion |
| Growth Rate | CAGR of 8.94% from 2019 to 2026 |
| Base year | 2019 |
| Forecast period | 2021–2026 |
| Forecast Unit (Value) | USD Billion |
| Segments covered | Product Type, Procedure, And Geography |
| Regions covered | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies covered | Edwards Lifesciences Corporation, Medtronic, Abbott, Boston Scientific Corporation or its affiliates, LivaNova PLC, CryoLife, Inc., Micro Interventional Devices, Inc. ,TTK Healthcare Limited, Lepu Medical Technology (Beijing) Co., Ltd., Comed B.V. |
| Customization scope | Free report customization with purchase |
Segmentation:
Frequently Asked Questions (FAQs)
Q1. What are the growth prospects for the structural heart devices market?
A1. The global structural heart devices market is expected to grow at a CAGR of 8.94% during the forecast period.
Q2. How is the global structural heart devices market segmented?
A2. The structural heart devices market has been segmented based on product type, procedure, and geography.
Q3. What will be the structural heart devices market size by 2026?
A3. The structural heart devices market is expected to reach a market size of US$10.086 billion in 2026.
Q4. What is the size of global structural heart devices market?
A4. Structural Heart Devices Market was valued at US$5.537 billion in 2019.
Q5. What factors are anticipated to drive the structural heart devices market growth?
A5. An increment sought after for structural heart devices has been seen, attributable to the ascent in the number of patients experiencing structural heart illnesses.
Edwards Lifesciences Corporation
Medtronic
Abbott
Boston Scientific Corporation
CryoLife, Inc.
Gyrus Capital
Micro Interventional Devices Inc.
OSCOR, Inc.
Comed B.V.
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.